<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="384">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03533257</url>
  </required_header>
  <id_info>
    <org_study_id>AMX-8000</org_study_id>
    <nct_id>NCT03533257</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease</brief_title>
  <acronym>PEGASUS</acronym>
  <official_title>Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amylyx Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Drug Discovery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amylyx Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will be a 24-week, randomized, double-blind, multi-site,&#xD;
      placebo-controlled study in volunteers with late mild cognitive impairment (MCI) or early&#xD;
      dementia due to Alzheimer's disease (AD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 24-week, randomized, double-blind, multi-site, placebo-controlled study in&#xD;
      volunteers with late mild cognitive impairment (MCI) or early dementia due to Alzheimer's&#xD;
      disease (AD). The study is designed to evaluate the safety, tolerability, drug target&#xD;
      engagement and neurobiological effects of treatment with AMX0035 over 24 weeks. The study is&#xD;
      designed to yield deep phenotyping insight for the purposes of demonstrating the effects of&#xD;
      AMX0035 on mechanistic targets of engagement and disease biology. The study will evaluate&#xD;
      diverse disease-relevant markers and produce an informative dataset that will allow for&#xD;
      evaluation and correlation of imaging-based markers, neurobiological changes, functional&#xD;
      measures, and cognitive outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Actual">August 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo-Controlled, Double-Blind, Parallel-Group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantity of Adverse Events Observed in the Study</measure>
    <time_frame>6 Months</time_frame>
    <description>Rate of Adverse Events between Placebo and Active Groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI Volumetric Imaging</measure>
    <time_frame>6 Months</time_frame>
    <description>Impact of AMX0035 on levels of whole brain atrophy, as assessed by volumetric Magnetic Resonance Imaging (vMRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>6 Months</time_frame>
    <description>Impact of AMX0035 on clinical symptoms as measured by ADAS-Cog</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Symptoms</measure>
    <time_frame>6 Months</time_frame>
    <description>Impact of AMX0035 on measures of neuropsychiatric symptoms as assessed by the Neuropsychiatric Inventory (NPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Hippocampal Imaging</measure>
    <time_frame>6 Months</time_frame>
    <description>Impact of AMX0035 on levels of hippocampal atrophy, as assessed by volumetric Magnetic Resonance Imaging (vMRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional MRI Imaging</measure>
    <time_frame>6 Months</time_frame>
    <description>Impact of AMX0035 on rsfMRI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CSF Biomarkers</measure>
    <time_frame>6 Months</time_frame>
    <description>Impact of AMX0035 on CSF biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Biomarkers</measure>
    <time_frame>6 Months</time_frame>
    <description>Impact of AMX0035 on plasma biomarkers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Active (AMX0035)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AMX0035--a combination of TUDCA and Phenylbutyrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Taste-matched Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMX0035</intervention_name>
    <description>Combination Therapy of TUDCA and Sodium Phenylbutyrate</description>
    <arm_group_label>Active (AMX0035)</arm_group_label>
    <other_name>Tauroursodeoxycholic Acid and Sodium Phenylbutyrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 55-89, inclusive, male or female&#xD;
&#xD;
          2. Diagnosis of &quot;Probable Alzheimer's Disease&quot; or Mild Cognitive Impairment (amnestic or&#xD;
             amnestic plus other) with biomarkers that suggest intermediate or high likelihood that&#xD;
             the syndrome is due to AD, according to 2011 NIA-AA Workgroup criteria&#xD;
&#xD;
          3. MoCA 8 - 26 inclusive&#xD;
&#xD;
          4. Able to read and write in English sufficiently to complete all study procedures&#xD;
&#xD;
          5. Geriatric Depression Scale &lt;7&#xD;
&#xD;
          6. Willing and able to complete all assessments and study procedures&#xD;
&#xD;
          7. Not pregnant, lactating or of child-bearing potential (women must be &gt;2 years&#xD;
             post-menopausal or surgically sterile)&#xD;
&#xD;
          8. Study partner with at least two days per week with contact with patient willing to&#xD;
             accompany patient to visits and complete partner study forms&#xD;
&#xD;
          9. No known hypersensitivity to Tauroursodeoxycholic acid or Phenylbutyrate&#xD;
&#xD;
         10. Must have a previous biomarker supportive of AD as the underlying pathology of&#xD;
             cognitive decline, which could include amyloid PET, CSF AD biomarkers, FDG-PET, or&#xD;
             vMRI scan&#xD;
&#xD;
         11. If on cholinesterase inhibitor and/or memantine, doses are stable for 3 months prior&#xD;
             to baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any CNS disease other than suspected AD, such as clinical stroke, brain tumor, normal&#xD;
             pressure hydrocephalus, multiple sclerosis, significant head trauma with persistent&#xD;
             neurological cognitive deficits or complaints, Parkinson's disease, frontotemporal&#xD;
             dementia, or other neurodegenerative diseases&#xD;
&#xD;
          2. Abnormal liver function defined as AST and/or ALT &gt; 3 times the upper limit of normal&#xD;
&#xD;
          3. Renal insufficiency as defined by a serum creatinine &gt; 1.5 times the upper limit of&#xD;
             normal&#xD;
&#xD;
          4. History of cholecystectomy or biliary disease&#xD;
&#xD;
          5. Clinically significant unstable medical condition (other than AD) that in the Site&#xD;
             Investigator opinion would pose a risk to the participant if they were to participate&#xD;
             in the study&#xD;
&#xD;
          6. Any contraindication to undergo MRI studies such as:&#xD;
&#xD;
               1. History of a cardiac pacemaker or pacemaker wires&#xD;
&#xD;
               2. Metallic particles in the body&#xD;
&#xD;
               3. Vascular clips in the head&#xD;
&#xD;
               4. Prosthetic heart valves&#xD;
&#xD;
               5. Severe claustrophobia impeding ability to participate in an imaging study&#xD;
&#xD;
          7. Major active or chronic psychiatric illness (e.g. depression, bipolar disorder,&#xD;
             obsessive compulsive disorder, schizophrenia) within the previous year prior to&#xD;
             baseline&#xD;
&#xD;
          8. Any significant neurodevelopmental disability&#xD;
&#xD;
          9. Current suicidal ideation or history of suicide attempt within five years of baseline&#xD;
             or significant change from the screening and baseline C-SSRS at the discretion of the&#xD;
             Site Investigator&#xD;
&#xD;
         10. History of alcohol or other substance abuse or dependence within the past two years&#xD;
&#xD;
         11. Any significant systemic illness or medical condition that could affect safety or&#xD;
             compliance with study at the discretion of the Site Investigator&#xD;
&#xD;
         12. Laboratory abnormalities in B12, TSH, or other common laboratory parameters that might&#xD;
             contribute to cognitive dysfunction&#xD;
&#xD;
         13. Current use of medications with psychoactive properties that may deleteriously affect&#xD;
             cognition (e.g., anticholinergics, centrally-acting antihistamines, antipsychotics,&#xD;
             sedative hypnotics, anxiolytics)&#xD;
&#xD;
         14. Use of any small molecule investigational therapy being used or evaluated for the&#xD;
             treatment of AD is prohibited beginning three months (84 days) prior to the Baseline&#xD;
             Visit and throughout the study.&#xD;
&#xD;
         15. Use of any immunotherapy investigational therapy is prohibited beginning one year (365&#xD;
             days) prior to the Baseline Visit and throughout the study.&#xD;
&#xD;
         16. Use of other investigational agents one month (28 days) prior to the Baseline Visit&#xD;
             and for the duration of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CNS Healthcare - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Investigational Centers (IMIC)</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Clinical Research Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rowan University</name>
      <address>
        <city>Stratford</city>
        <state>New Jersey</state>
        <zip>08084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Alzheimer's Disease Research Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Memory Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Biomedical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>May 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2018</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodoxicoltaurine</mesh_term>
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

